tetano
Editor, Senior Moderator
ESC Heart Fail
. 2021 Jan 14.
doi: 10.1002/ehf2.13175. Online ahead of print.
Heart failure with preserved ejection fraction in coronavirus disease 2019 patients: the promising role of diuretic therapy in critically ill patients
Mitra Chitsazan[SUP] 1 [/SUP], Ahmad Amin[SUP] 1 [/SUP], Mandana Chitsazan[SUP] 2 [/SUP], Naghmeh Ziaie[SUP] 3 [/SUP], Parviz Amri Maleh[SUP] 3 [/SUP], Hamidreza Pouraliakbar[SUP] 1 [/SUP], Stephan Von Haehling[SUP] 4 [/SUP]
Affiliations
Abstract
The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on diastolic function is less known. We describe a 46-year-old man with a history of mild hypertension who presented to the emergency department with fever, cough, and myalgia for 2 days. The patient was tested positive for SARS-CoV-2. He was admitted and started on a combination of antiviral and antimicrobial therapy. He developed respiratory distress 2 days later, and O[SUB]2[/SUB] saturation declined. Blood tests showed an increased N-terminal pro-B type natriuretic peptide (NT-proBNP) level, and echocardiography showed normal left ventricular ejection fraction and E/e' ratio of 16. Computed tomography scan showed interstitial pulmonary oedema and prominent peripheral pulmonary vascular markings. Given these findings, heart failure with preserved ejection fraction (HFpEF) was considered. Low-dose diuretic was started, and fluid administration was restricted, resulting in a decrease in NT-proBNP level, clinical and haemodynamic stabilization, and improved oxygenation. This case highlights the occurrence of HFpEF in coronavirus disease 2019.
Keywords: COVID-19; Diastolic heart failure; Diuretic; Heart failure with preserved ejection fraction (HFpEF); N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP); Pandemic; SARS-CoV-2.
. 2021 Jan 14.
doi: 10.1002/ehf2.13175. Online ahead of print.
Heart failure with preserved ejection fraction in coronavirus disease 2019 patients: the promising role of diuretic therapy in critically ill patients
Mitra Chitsazan[SUP] 1 [/SUP], Ahmad Amin[SUP] 1 [/SUP], Mandana Chitsazan[SUP] 2 [/SUP], Naghmeh Ziaie[SUP] 3 [/SUP], Parviz Amri Maleh[SUP] 3 [/SUP], Hamidreza Pouraliakbar[SUP] 1 [/SUP], Stephan Von Haehling[SUP] 4 [/SUP]
Affiliations
- PMID: 33442925
- DOI: 10.1002/ehf2.13175
Abstract
The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on diastolic function is less known. We describe a 46-year-old man with a history of mild hypertension who presented to the emergency department with fever, cough, and myalgia for 2 days. The patient was tested positive for SARS-CoV-2. He was admitted and started on a combination of antiviral and antimicrobial therapy. He developed respiratory distress 2 days later, and O[SUB]2[/SUB] saturation declined. Blood tests showed an increased N-terminal pro-B type natriuretic peptide (NT-proBNP) level, and echocardiography showed normal left ventricular ejection fraction and E/e' ratio of 16. Computed tomography scan showed interstitial pulmonary oedema and prominent peripheral pulmonary vascular markings. Given these findings, heart failure with preserved ejection fraction (HFpEF) was considered. Low-dose diuretic was started, and fluid administration was restricted, resulting in a decrease in NT-proBNP level, clinical and haemodynamic stabilization, and improved oxygenation. This case highlights the occurrence of HFpEF in coronavirus disease 2019.
Keywords: COVID-19; Diastolic heart failure; Diuretic; Heart failure with preserved ejection fraction (HFpEF); N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP); Pandemic; SARS-CoV-2.